Metabolic and hemodynamic effects of the growth hormone system — insulin-like growth factor


Cite item

Full Text

Abstract

Significant congenital deficiency of growth factor (GF) results in pituitary nanism (dwarfism) and its substantial excess is accompanied by the development of gigantism or acromegaly. Its impact on the growth of the whole body or its individual parts is impossible without affecting metabolic processes and hemodynamic parameters. A number of investigations have proven that GF has a direct lipolytic effect: adequate replacement therapy for pituitary nanism gives rise to a reduction in fat depots. Since the concentration of GF is lower in obesity, whether it may be used to treat this abnormality is considered.

About the authors

T A Manhylova

N H Gafarova

References

  1. Koch CH, Chrousos GP. Endocrine hypertension. In: Towie DHP, Merriam JR, eds. Hypertension in growth hormone excess and deficiency. Humana Press; 2013:151-179.
  2. Воротникова С.Ю., Пигарова У.А., Дзеранова Л.К. Метаболические эффекты гормона роста. Ожирение и метаболизм. 2011;4:55-59.
  3. Bartke A, Westbrook R, Sun L, Ratajczak M. Links between growth hormone and aging. Endokrynol Pol. 2013;64:46-52.
  4. Brown-Borg HM, Bartke A. GH and IGF-1: roles in energy metabolism of long-living GH-mutant mice. J Gerontol A Biol SciMed. Sci. 2012;67A:652-660.
  5. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocrine Rev. 2012;33:314-377. doi: 10.1210/er.2012-1002.
  6. Møller N, Copeland KC, Nair KS. Growth hormone and protein metabolism. Clin Nutrition. 2009;28:597-603.
  7. Yuen KC, Dunger DB. Impact of treatment with recombinant human GH and IGF-1 on visceral adipose tissue and glucose homeostasis in adult. Growth Horm IGF Res. 2006;16:55-61.
  8. Yuen KC, Dunger DB. Terapeutic aspects of growth hormone and insulin-like growth factor treatment on visceral fat and insulin sensitivity in adult. Diabetes Obes Metab. 2007;9:11-22.
  9. Moller N, Jorgensen O. Effects of growth hormone on glucose, lipid and protein metabolism in human subjects. Endocrine Rev. 2009;3:152-177.
  10. Attalah H, Friedlander AL, Hoffman AR. Visceral obesity, impaired glucose tolerance, and growth hormone therapy. GrowthHorm IGF Res. 2006;16:62-67.
  11. Berryman DI, Glad C, List EO, Johannsson G. The GH/IGF axis in obesity: pathophysiology and therapeutic considerations. NatureRev Endocrinol. 2013;9:346-356.
  12. Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR. Effects of growth hormone and piolglitazone in viscerally obese adults with impaired glucose tolerance: a fractional clinical trial. PloS Clin Trials. 2007;2:e21.
  13. Cornford AS, Barkan AL, Horowitz JF. Rapid suppression of growth hormone concentration by overeating: potential mediator by hyperinsulinemia. JCEM. 2011;96:824-830.
  14. Дедов И.И., Петеркова В.А., Нагаева Е.В. Гормон роста в современной клинической практике. Лечащий врач. 2007;2:22-27.
  15. Курляндская Р.М., Черпаков А.Б., Романцова Т.И., Мельниченко Г.А. Возможности медикаментозной коррекции недостатка гормона роста у взрослых. Лечащий врач. 2001;9:4-8.
  16. Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf). 2011;75:220-225. doi: 10.1111/j.1365-2265.2011.04019.x.
  17. Elbornsson M, Götherström G, Bosæus I, Bengtsson BÅ, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168:745-753. doi: 10.1530/eje-12-1083.
  18. Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J, Macfarlane IA. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res. 2010;20:220-225. doi: 10.1016/j.ghir.2010.02.002.
  19. Barreto-Filho JA, Alcântara MR, Salvatori R, Barreto MA, Sousa AC, Bastos V, Souza AH, Pereira RM, Clayton PE, Gill MS, Aguiar-Oliveira MH. Familiar isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity and dyslipidemia. J Clin Endocrinol Metab. 2002;87:2018-2023.
  20. Bondanelly M, Ambrosio MR, Degli-Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4:239-249.
  21. Дедов И.И., Молитвословова Н.Н., Рожинская Л.Я., Мельниченко Г.А. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения акромегалии. Проблемы эндокринологии. 2013;6:4-18.
  22. Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC. GH and IGF-1 control contributes to blood pressure control: results of an observational retrospective multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol (Oxf.). 2008;69:613-620. doi: 10.1111/j.1365-2265.2008.03258.x.
  23. Tivesten A, Barlind A, Caidahl K, Klintland N, Cittadini A, Ohlsson C, Isgaard J. Growth hormone-induced blood pressure decrease is associated with increased nRNA levels of the vascular smooth muscle Katp channel. J Endocrinol. 2004;183:195-202.
  24. Faje AT, Barkan AL. Basal, but not pulsatile growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-1. JCEM. 2010;95:2486-2491.
  25. Puche JE, Castilla-Cortazar E. Human conditions of insulin-like growth factor-1 (IGF-1) deficiency. J Transl Med. 2012;10:224-235.
  26. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson BA. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol(Oxf). 1994;41:351-357.
  27. Delafontaine P, Song Y-H, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscleros, Thrombos Vasc Biol. 2004;24:435-444.
  28. Zachariah JP, Xanthakis V, Larson MG, Vita JA, Sullivan LM, Smith HM, Safa R, Peng X, Hamburg N, Levy D, Sawyer DB, Mitchell GF, Vasan RS. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension. 2012;59:773-779. doi: 10.1161/hypertensionaha.111.179242.
  29. Lopez-Lopez C, LeRoith D, Torres-Aleman I. Insulin-like growth factor I is required for vessels remodeling in the adult brain. PNAS. 2004;101:9833-9838.
  30. Hypponen E, Boucher BJ, Berry D. Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes. 2008;57:298-305.
  31. Capoluongo E, Pitocco D, Lulli P. Inverse correlation between serum free IGF-1 and IGFBP-3 levels and blood pressure in patients affected with type I diabetes. Cytokine. 2006;34:303-311.
  32. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-1. Endocrinology. 2007;148:2435-2443.
  33. Perticone F, Sciacqua A, Perticone M, Laino I, Miceli S, Care’ I, Galiano Leone G, Andreozzi F, Maio R, Sesti G. Low plasma insulin-like growth factor-1 levels are associated with impaired endothelium dependent vasodilatation in a cohort of untreated hypertensive Caucasian subjects. Endocrine Res. 2008;93:2806-2810. doi: 10.1210/jc.2008-0646.
  34. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci. 2012;67A:626-639. doi: 10.1093/gerona/gls102.
  35. Zhang L, Curhan GC, Forman JP. Plasma insulin-like growth factor-1 level and risk of incident hypertension in non-diabetic women. J Hypertens. 2011;29:229-235. doi: 10.1097/hjh.0b013e32834103bf.
  36. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, Santeusanio F, Porcellati C, Brunetti P. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 1999;100:1802-1807.
  37. Nguyen TT, Cao N, Short JL, White PJ. Intravenous Insulin-like growth factor-1 receptor antisense treatment reduces angiotensin receptor expression and function in spontaneously hypertensive rats. JPET. 2006;318:1171-1177.
  38. Hunt KJ, Lukanova A, Rinaldi S, Lundin E, Norat T, Palmqvist R, Stattin P, Riboli E, Hallmans G, Kaaks R. A potential inverse association between insulin like growth factor-1 and hypertension in cross-sectional study. Ann Epidemiol. 2006;16:563-571.
  39. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, Lombardi G, Savastano S. Relationships between serum IGF-1 levels, blood pressure and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159:389-397. doi: 10.1530/eje-08-0201.
  40. Andronico G, Mangano MT, Nardi E, Mulè G, Piazza G, Cerasola G. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens. 1993;10:1097-1101.
  41. Diez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinipril and quinaprili. J Hypertension. 1994;12:31-36.
  42. Colangelo LA, Liu K, Capstur SM. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and cardiovascular disease risk factors in young black men and white men: the CARDIA male hormone study. Am J Epidemiol. 2004;160:750-757.
  43. Paolisso G, Tagliamonte MR, Rizzo MR, Rotondi M, Gualdiero P, Gambardella A, Barbieri M, Carella C, Giugliano D, Varricchio M. Mean arterial blood pressure and serum levels of the molar ratio of insulin-like growth factor-1 to its binding protein-3 in healthy centenarians. J Hypertens. 1999;18:67-73.
  44. Unden AL, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein to cardiovascular risk factors: a population-based study. Clin Endocrinol (Oxf). 2005;63:94-102.
  45. Yeap BB, Chubb SA, Ho KK, Setoh JW, McCaul KA, Norman PE, Jamrozik K, Flicker L. IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men. EurJ Endocrinol. 2010;162:249-257. doi: 10.1530/eje-09-0852.
  46. Akanii AO, Smeth RJ. The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr RelatDisord. 2012;10:3-13. doi: 10.1089/met.2011.0083.
  47. Garg V. Noninsulin pharmacological management of type I diabetes mellitus. Indian J Endocrinol Metab 2011;15(Suppl 1):5-11. doi: 10.4103/2230-8210.83053.
  48. Rosenbloom AL. Mecasermin (recombinant insulin-like growth factor I). Adv Ther. 2009;26:40-54.
  49. Arnetz L, Rajamand Ekberg N, Höybye C, Brismar K, Alvarsson M. Improved insulin sensitivity during pioglitazone treatment is associated with changes in IGF-1 and cortisol secretion in type 2 diabetes and impaired glucose tolerance. ISRN Endocrinol. 2013;2013:148497. doi: 10.1155/2013/148497.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies